Mezlocillinにかんする基礎的ならびに臨床的研究

DOI Web Site

書誌事項

タイトル別名
  • BASIC AND CLINICAL STUDIES ON MEZLOCILLIN
  • Mezlocillin ニ カンスル キソテキ ナラビニ リンショウテキ ケン

この論文をさがす

抄録

Mezlocillin has been investigated and the following results were obtained.<BR>1. The peak of susceptibility distribution of clinical isolates ofStaph. aureus, E. coli, Klebsiella, Proteus sp. andPs. aeruginosato mezlocillin were, in lower inoculum size of bacteria, 1.56, 3.12, 6.25, 1.56 and 25 μg/ml, respectively.<BR>Antibacterial activity of mezlocillin against the a. m. clinical isolates except Proteus sp. was found to be superior to that of carbenicillin in lower inoculum size.<BR>Antibacterial activity of mezlocillin againstKlebsiellaand E. coli was influenced by inoculum size of bacteria.<BR>2. Four grams of mezlocillin was given intravenously to a patient with normal renal function. The serum level of mezlocillin 15 minutes after administration was 180 μg/ml and its biological half-life period was approximately 45 minutes.<BR>The urinary recovery rate within 6 hours after administration of mezlocillin was about 38.0%. A markedly prolonged half-life period of serum level of mezlocillin was observed in a patient with impaired renal function.<BR>3. Mezlocillin was administered to patients with septicemia in 1 case, chronic bronchitis in 1 case, bronchopneumonia in 1 case and infected lung cancer in 2 cases, at a daily dose of 4-12 g for 3-16 days. The results obtained were excellent in 1 case, good in 3 cases and poor in 1 case.<BR>As for side effects, pyrexia and elevation of GOT, GPT in 1 case and pyrexia in 1 case were observed.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ